Dimethylcurcumin-loaded methoxypolyethylene glycol-dimethylcurcumin conjugate nanoparticles: preparation, characterization and in vitro antitumor study
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Wang G et al (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105–114010.1101/gad.315739.118 ↗
2. Yanagisawa T et al (2022) Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 82:584–59810.1016/j.eururo.2022.08.002 ↗
3. Mansinho A et al (2018) Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. Adv Exp Med Biol 1096:117–13310.1007/978-3-319-99286-0_7 ↗
4. Dai C, Heemers H, Sharifi N (2017) Androgen Signaling in Prostate Cancer. Cold Spring Harb Perspect Med 7:a03045210.1101/cshperspect.a030452 ↗
5. Aurilio G et al (2020) Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. Cells 9:265310.3390/cells9122653 ↗
6. Lai C, Hu H, Xu D (2021) Encapsulation and Delivery of Dimethylcurcumin by Using Nanoparticles of a Polyethylene-Glycol-Based Dimethylcurcumin Prodrug. ChemistrySelect 6:3013–302110.1002/slct.202100239 ↗
7. Wieczorek E, Farooqi AA, Reszka E (2022) Androgen receptor modulation and bladder cancer prevention - a short review. Med Pr 73:151–16210.13075/mp.5893.01229 ↗
8. Kanda T, Jiang X, Yokosuka O (2014) Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers. World J Gastroenterol 20:9229–923610.3748/wjg.v20.i26.8535 ↗
9. He D et al (2014) ASC-J9 suppresses renal cell carcinoma progression by targeting an androgen receptor-dependent HIF2α/VEGF signaling pathway. Cancer Res 74:4420–344010.1158/0008-5472.CAN-13-2681 ↗
10. Tran C et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787–79010.1126/science.1168175 ↗
11. Korpal M et al (2013) An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 3:1030–104310.1158/2159-8290.CD-13-0142 ↗
12. Chen J et al (2017) Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression. Cancer Lett 408:155–16310.1016/j.canlet.2017.08.014 ↗
13. Ahmed NN et al (2019) Food matrix and co-presence of turmeric compounds influence bioavailability of curcumin in healthy humans. Food Funct 10:4584–459210.1039/C9FO01063G ↗
14. Ibrahim SG et al (2020) Dimethyl fumarate and curcumin attenuate hepatic ischemia/reperfusion injury via Nrf2/HO-1 activation and anti-inflammatory properties. Int Immunopharmacol 80:10613110.1016/j.intimp.2019.106131 ↗
15. Hu H, Zhou H, Xu D (2021) A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. Chem Biol Drug Des 97:821–83510.1111/cbdd.13811 ↗
16. Lai KP et al (2013) New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 182:460–47310.1016/j.ajpath.2012.10.029 ↗
17. Kanda T, Yokosuka O (2015) The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma 2:91–9910.2147/JHC.S48956 ↗
18. Miyamoto H et al (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99:558–56810.1093/jnci/djk113 ↗
19. Zhu W et al (2019) Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals. Cell Death Dis 10:27510.1038/s41419-019-1358-y ↗
20. Huang CK et al (2016) Androgen receptor (AR) in cardiovascular diseases. J Endocrinol 229:1–1610.1530/JOE-15-0518 ↗
21. Hu H et al (2019) Methoxylpoly(ethylene glycol)-retinoic acid Micelles Loaded with Dimethylcurcumin for Efficient Castration-Resistant Prostate Cancer Therapy. ChemistrySelect 4:12015–1202110.1002/slct.201902562 ↗
22. Myung JK et al (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123:2948–6010.1172/JCI66398 ↗
23. Hu H, Xu D (2022) pH-Sensitive nanoparticles co-loaded with dimethylcurcumin and regorafenib for targeted combinational therapy of hepatocellular carcinoma. Eur Polymer J 177:11143410.1016/j.eurpolymj.2022.111434 ↗
24. Chen Y et al (2021) Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK. Toxicol In Vitro 76:10522610.1016/j.tiv.2021.105226 ↗
25. Zhou H et al (2019) Design and evaluation of a solid dispersion and thermosensitive hydrogel combined local delivery system of dimethoxycurcumin. Journal of Drug Delivery Science and Technology 53:10115010.1016/j.jddst.2019.101150 ↗
26. Hu H et al (2020) Branched worm-like nanoparticles featured with programmed drug release for synergistic castration-resistant prostate cancer therapy. J Mater Sci 55:6992–700810.1007/s10853-020-04495-9 ↗
27. Wang Y, Sun T, Jiang C (2022) Nanodrug delivery systems for ferroptosis-based cancer therapy. J Control Release 344:289–30110.1016/j.jconrel.2022.01.034 ↗
28. Adepu S, Ramakrishna S (2021) Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules 26:590510.3390/molecules26195905 ↗
29. Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–1810.1016/j.colsurfb.2009.09.001 ↗
30. Zielińska A et al (2020) Polymeric Nanoparticles: Production, Characterization. Toxicology and Ecotoxicology Molecules 25:3731
31. Suk JS et al (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–5110.1016/j.addr.2015.09.012 ↗
32. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–145810.1016/S1359-6446(05)03575-0 ↗
33. Chen Z et al (2014) Thermal degradation kinetics study of curcumin with nonlinear methods. Food Chem 155:81–8610.1016/j.foodchem.2014.01.034 ↗
34. Guo S et al (2020) Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(1):e158210.1002/wnan.1582 ↗
35. Dharmayanti C et al (2021) Strategies for the Development of pH-Responsive Synthetic Polypeptides and Polymer-Peptide Hybrids: Recent Advancements. Polymers (Basel) 13(4):32–4610.3390/polym13040624 ↗
36. Cheng X, Lee RJ (2016) The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev 99(Pt A):129–13710.1016/j.addr.2016.01.022 ↗
37. Sell M et al (2023) Application of Nanoparticles in Cancer Treatment: A Concise Review. Nanomaterials (Basel) 13(21):288710.3390/nano13212887 ↗
38. He ZY et al (2014) Recent development of poly(ethylene glycol)-cholesterol conjugates as drug delivery systems. Int J Pharm 469(1):168–17810.1016/j.ijpharm.2014.04.056 ↗
39. van Hees M et al (2022) New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape. Mol Ther 30(1):32–4610.1016/j.ymthe.2021.06.003 ↗
40. Lai KP et al (2013) Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol 27(10):1617–163110.1210/me.2013-1207 ↗